BRIEF-CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream Accepted

Reuters
Yesterday
BRIEF-CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream Accepted

Feb 24 (Reuters) - China Medical System Holdings Ltd 0867.HK:

  • CMS (867.HK/8A8.SG): NDA FOR ADDITIONAL INDICATION ATOPIC DERMATITIS $(AD)$ FOR RUXOLITINIB PHOSPHATE CREAM ACCEPTED AND GRANTED PRIORITY REVIEW IN CHINA

  • CHINA MEDICAL SYSTEM HOLDINGS - REVIEW TIMELINE SHORTENED FROM 200 DAYS TO 130 DAYS

Source text: ID:nGNX93bPCr

Further company coverage: 0867.HK

(((( Reuters.briefs@thomsonreuters.com ;));))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10